

	Placebo (N=6)		IL7 3µg/kg (N=6)		IL7 10 µg/kg (N=6)		IL7 30 µg/kg (N=3)		IL7 60 µg/kg (N=3)	
Toxicities/Toxicity Grade	2	3	2	3	2	3	2	3	2	3
General Body	1		1		1		1		1	
Respiratory							1		1	
Endocrine	1									
Metabolic	1		1		1		1		1	
Liver/Hepatic			1		1	1 ^A				1 ^B
Gastrointestinal					1				1	
Skin										1 ^C
Neurological			1		1				1	
Any toxicity*	3	0	2	0	1	1	2	0	1	2

A. Elevated total bilirubin in atazanavir recipient (at week 1; classified as not related to study treatment)

B. Elevated Alanine Aminotransferase (ALT), elevated gamma glutamyl transpeptidase (GGTP), SGPT (all at week 1; classified as possibly/probably and possibly, to study treatment respectively)

C. Induration; induration at the site of injection (at week 1; classified as definitely related to study treatment)

* NOTE: This represents the distinct number of subjects who reported ANY toxicity. A subject may report multiple toxicities but the subject was only counted once in the “Any toxicity” category.